These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15955594)

  • 1. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
    Kitazaki T; Oka M; Nakamura Y; Tsurutani J; Doi S; Yasunaga M; Takemura M; Yabuuchi H; Soda H; Kohno S
    Lung Cancer; 2005 Sep; 49(3):337-43. PubMed ID: 15955594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
    Tsai CM; Chiu CH; Chang KT; Chen JT; Lai CL; Chen YM; Hsiao SY
    J Thorac Oncol; 2012 Aug; 7(8):1218-27. PubMed ID: 22659964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
    Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
    Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
    Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
    Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.
    Tao LY; Liang YJ; Wang F; Chen LM; Yan YY; Dai CL; Fu LW
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):961-9. PubMed ID: 19255759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.
    Mi Y; Lou L
    Br J Cancer; 2007 Oct; 97(7):934-40. PubMed ID: 17912240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
    Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
    Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
    Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
    Koizumi F; Shimoyama T; Taguchi F; Saijo N; Nishio K
    Int J Cancer; 2005 Aug; 116(1):36-44. PubMed ID: 15761868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
    Elkind NB; Szentpétery Z; Apáti A; Ozvegy-Laczka C; Várady G; Ujhelly O; Szabó K; Homolya L; Váradi A; Buday L; Kéri G; Német K; Sarkadi B
    Cancer Res; 2005 Mar; 65(5):1770-7. PubMed ID: 15753373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.